ORCID Profile
0000-0002-6537-6215
Current Organisation
Southern Medical University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 03-2016
DOI: 10.1038/SREP22485
Abstract: To evaluate the burden of air pollution on years of life lost (YLL) in addition to mortality, we conducted a time series analysis based on the data on air pollution, meteorological conditions and 163,704 non-accidental deaths of Ningbo, China, 2009–2013. The mean concentrations of particulate matter with aerodynamic diameter μm, particulate matter with aerodynamic diameter .5 μm, sulfur dioxide and nitrogen dioxide were 84.0 μg/m 3 , 60.1 μg/m 3 , 25.1 μg/m 3 and 41.7 μg/m 3 , respectively. An increase of 10-μg/m 3 in particulate matter with aerodynamic diameter μm, particulate matter with aerodynamic diameter .5 μm, sulfur dioxide and nitrogen dioxide was associated with 4.27 (95% confidence interval [CI] 1.17–7.38), 2.97 (95% CI −2.01–7.95), 29.98 (95% CI 19.21–40.76) and 16.58 (95% CI 8.19–24.97) YLL, respectively and 0.53% (95% CI 0.29–0.76%), 0.57% (95% CI 0.20–0.95%), 2.89% (95% CI 2.04–3.76%) and 1.65% (95% CI 1.01–2.30%) increase of daily death counts, respectively. The impact of air pollution lasted for four days (lag 0–3) and were more significant in the elderly than in the young population for both outcomes. These findings clarify the burden of air pollution on YLL and highlight the importance and urgency of air pollution control in China.
Publisher: Informa Healthcare
Date: 29-01-2013
DOI: 10.1185/03007995.2013.766594
Abstract: A great number of clinical trials and systematic reviews have evaluated the efficacy and safety of α(1) blockers for benign prostatic hyperplasia (BPH). We carried out an overview of reviews to provide an up-to-date summary of evidence regarding the efficacy and safety between different α(1) blockers for BPH. PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature Database and VIP were searched for eligible studies. Direct evidence was analyzed narratively. We used a random-effects model within a Bayesian framework to calculate indirect estimates if no direct evidence existed. The GRADE approach was used in summarizing conclusions. A total of 15 systematic reviews involving five α(1) blockers met the inclusion criteria. Direct evidence demonstrated that α(1) blockers were superior to placebo in reducing urinary symptom scores and improving peak urinary flow PUF. Doxazosin could significantly reduce urinary symptom scores compared with tamsulosin mean difference (MD -1.60, 95% CI -1.80 to -1.40) and alfuzosin (MD1.7, 95% CI 0.76-1.64). Indirect evidence suggested that the urinary symptom score and PUF at endpoint in men treated with naftopidil were similar to those treated with other α(1) blockers. α(1) Blockers generally lead to more adverse effects compared with placebo, and those caused by terazosin were more frequent than others. α(1) Blockers are more effective than placebo for BPH, doxazosin and tamsulosin seem to be more effective than other α(1) blockers. The adverse effects caused by α(1) blockers are generally mild and well-tolerated.
Publisher: Elsevier BV
Date: 05-2013
DOI: 10.1016/J.EURURO.2013.01.012
Abstract: Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited. To compare the efficacy and safety of different classes of oral PDE5-Is for ED. A systematic search was performed in PubMed, Cochrane Library, and Embase to identify randomized controlled trials that compared different PDE5-Is or PDE5-Is with a placebo for ED. The methodological quality of included studies was appraised with the Cochrane Collaboration bias appraisal tool, and the quality of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation system. A total of 118 trials (31 195 in iduals) were included. There was no major difference in the results between the traditional meta-analysis and the network meta-analysis. Network meta-analysis demonstrated that PDE5-Is were superior to placebo to improve erectile function. Compared with tadalafil (relative risk [RR]: 0.61 95% confidence interval [CI], 0.33-0.90) and vardenafil (RR: 0.63 95% CI, 0.35-0.92), avanafil was less effective on Global Assessment Questionnaire question 1. Tadalafil was more effective than vardenafil (mean difference [MD]: 1.49 95% CI, 0.50-2.50) and udenafil (MD: -1.84 95% CI, -3.31 to -0.33) as measured by the erectile function domain of the International Index of Erectile Function. For all efficacy outcomes, the absolute effects and the rank tests indicated that tadalafil and vardenafil were the most effective agents. After adjusting for dosage, the conclusion remained the same. Safety analysis showed there was no major difference among different agents. In recommended doses, oral PDE5-Is are more effective than placebo for ED, and tadalafil seems to be the most effective agent, followed by vardenafil. PDE5-Is are generally safe and well tolerated, and there is no major difference on the safety profile.
Publisher: Oxford University Press (OUP)
Date: 04-02-2014
DOI: 10.1093/RHEUMATOLOGY/KET418
Abstract: Vitamin D receptor (VDR) gene polymorphisms may be associated with the risk of OA, however, evidence for this is controversial. This meta-analysis aims to confirm whether VDR gene polymorphisms are associated with OA. Meta-analyses on the association between OA and VDR ApaI, BsmI, TaqI and FokI polymorphisms were conducted using allele and homozygote contrast and contrasts in the recessive and dominant models. Stratification analyses by different demographic regions (Europe vs Asian) were also performed and pooled odds ratios (ORs) were obtained using the random effects model if the results were heterogeneous. A total of 13 relevant studies involving OA patients (n = 2104) and controls (n = 2939) were included in the analysis. There were significant associations between VDR ApaI polymorphisms and OA in the Asian population (A vs a: OR= 1.16, 95% CI 1.02, 1.32, P = 0.025 AA vs Aa/aa: OR= 1.36, 95% CI 1.04, 1.77, P = 0.025 AA vs aa: OR= 1.35, 95% CI 1.00, 1.80, P = 0.047), but not in the whole population. There was also a statistically significant association between FokI polymorphism and OA (FF vs Ff/ff: OR= 0.65, 95% CI 0.44, 0.95, P = 0.024) however, this result was derived from only two studies. No significant associations were found between VDR TaqI and BsmI polymorphisms and OA. There are modest but statistically significant associations between VDR ApaI polymorphisms and the susceptibility of OA in the Asian population.
No related grants have been discovered for Chen Mao.